“…However, it was soon discovered that high doses of D1/5R agonists, or very high levels of DA release in PFC, as occurs during stress exposure, could be as detrimental to cognitive function as DA depletion, and the detrimental effects of stress involved excessive stimulation of D1/5R Goldman-Rakic, 1990, 1998;Murphy et al, 1996). The administration of D1/5R-selective agonists (SKF38393 [1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol], SKF81297 [(6)-6-chloro-2,3,4,5-tetrahydro-1-phenyl-1H-3-benzazepine], A77636 [1R-cis-1-(aminomethyl)-3,4-dihydro-3-tricyclo[3.3.1.13,7] dec-1-yl-[1H]-2-benzopyran-5,6-diol]) revealed an inverted U-shaped dose response, where either high-dose D1/5R antagonist or D1/5R agonist treatment impaired performance after systemic or intra-PFC infusions, whereas low doses of agonist improved performance, especially in monkeys with DA depletion (Arnsten et al, 1994; Prefrontal Dopamine and Cognitive Disorders Cai and Arnsten, 1997;Zahrt et al, 1997;Gamo et al, 2015). Later studies found parallel, inverted U-shaped influences on dlPFC neuronal physiology (Williams and Goldman-Rakic, 1995;Vijayraghavan et al, 2007;Arnsten et al, 2009), as described in detail below.…”